Chitogel

What Chitogel does

Chitogel is a New Zealand-based medical device company that develops and commercializes a chitosan-based hydrogel nasal dressing used as post-operative care following endoscopic sinus surgery (ESS). The core product, the Chitogel Endoscopic Sinus Surgery Kit, combines three naturally derived ingredients — Chitosan Succinamide, Dextran Aldehyde, and Glycerol — to control bleeding, reduce adhesion formation, decrease ostial stenosis, and improve patient comfort relative to traditional nasal packing. The product is supported by 18+ peer-reviewed clinical publications and is regulated as a Class III medical device with FDA 510(k) clearance (2018), CE Mark certification (April 2021), and TGA approval in Australia. Chitogel is headquartered in Wellington, with manufacturing at an EN ISO 13485:2016-certified facility, and currently distributes in the United States, Australia, and New Zealand with European expansion planned following CE Mark approval.

Name

Chitogel

Legal name

Chitogel Limited

Website

https://chitogel.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Chitogel is a New Zealand medical device company that sells a chitosan-based hydrogel nasal dressing (Endoscopic Sinus Surgery Kit) to hospitals and ENT surgeons for post-operative care following endoscopic sinus surgery, distributed across the US, Australia, and New Zealand.

Ownership category

akta.pro rank

Product category

ENT Surgical Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)

akta.pro secondary industry

Rhinology & Sinus Surgery (HLAKAMAD)

Keywords

• Post-operative sinus dressing
• Hydrogel wound healing
• Endoscopic sinus surgery
• ENT surgical supplies
• Nasal dressing medical device

Headquarters

HQ city

Wellington

HQ country

New Zealand

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales - Endoscopic Sinus Surgery Kit: Chitogel generates revenue through the sale of its Chitogel Endoscopic Sinus Surgery Kit to hospitals and ENT surgeons. This is a one-time product sale for each surgical procedure. The company is expanding its sales operations in the United States following a $6.58M investment.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Chitogel manufactures and sells the Chitogel Endoscopic Sinus Surgery Kit, a post-operative hydrogel nasal dressing applied to sinuses after endoscopic sinus surgery. The product combines Chitosan Succinamide, Dextran Aldehyde, and Glycerol to control bleeding, prevent adhesions and scarring, enhance wound healing, and improve patient comfort. The company also has pipeline products including an Otologic Kit for middle ear surgery and applications for laminectomy and abdominal surgery.

Product overview

Chitogel offers a portfolio of hydrogel-based wound healing products for surgical applications. The core product is the Chitogel Endoscopic Sinus Surgery Kit, a post-operative nasal dressing for endoscopic sinus surgery. The product portfolio includes the main Chitogel ESS Kit and pipeline products including an Otologic Kit for middle ear surgery, and applications for laminectomy and abdominal surgery. All products utilize a proprietary hydrogel formulation derived from natural ingredients (chitosan, dextran, and glycerol) to support wound healing, reduce adhesions, and improve patient outcomes.

Differentiator

Problem solved

Functional benefit

Products and services

• Chitogel Endoscopic Sinus Surgery Kit A post-operative hydrogel nasal dressing applied to sinuses after endoscopic sinus surgery (FESS). The kit contains everything needed to prepare, mix and apply the hydrogel, which combines Chitosan Succinamide, Dextran Aldehyde, and Glycerol to control bleeding, enhance wound healing, prevent scarring and adhesions, and improve patient comfort. Sold to hospitals and ENT surgeons; gel preparation and setting takes approximately 20 minutes and 10 mL is applied to each side.

Quantifiable outcome

• 73% improvement in frontal ostial area at 12 months post-surgery
• +8 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• SalesForce4Hire, LLCcoreChannel Partner/ Reseller/ Distributor · 7 October 2024McGeever's commercial execution arm that will establish and manage the dedicated medical sales team across the United States for Chitogel products.
• DQS Medizinprodukte GmbHminorOthers · 20 August 2020EU Notified Body based in Frankfurt am Main that certified Chitogel's EN ISO 13485:2016 quality management system. Part of the global DQS Group, focusing on assessment and certification of management systems for medical devices.
• New Zealand Trade and Enterprise (NZTE)coreGTM or Marketing Partner · 6 August 2020New Zealand government's international business development agency. Chitogel was promoted to NZTE's Focus 700 customer segment, recognizing the company's success as a kiwi medical device company and strong potential for international growth. NZTE helps connect businesses with right partners and investors for growth.

Scale indicators18 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Conmed Corporation: Medical device company with a dedicated ENT and general surgery product portfolio including hemostatic agents and surgical supplies used in sinus surgery. Conmed is an adjacent competitor in the FESS supply market.
• Integra LifeSciences: Medical device company with neurosurgery, ENT, and regenerative tissue products. Integra's ENT and dural repair portfolio includes products used in sinus and skull base surgery, making it an adjacent competitor in the Chitogel surgical specialty.
• Stryker: Diversified medical device company with ENT surgical instruments and equipment for sinus surgery. Stryker competes broadly in the FESS OR and offers competing surgical solutions across multiple specialties, including wound management.
• Smith+Nephew: Global medical technology company with a substantial advanced wound management portfolio. While not a direct nasal dressing competitor, Smith+Nephew's wound care franchise provides a benchmark for commercialization of advanced wound healing technologies across global markets.
• Medtronic: Global medical device leader with a substantial ENT/sinus surgery portfolio including nasal dressings, surgical instruments, and image-guided surgery systems. Competes broadly with Chitogel in FESS OR supply and is a relevant benchmark for commercial scale and surgeon relationships in ENT.
• Ethicon (Johnson & Johnson MedTech): J&J's surgical solutions business with hemostats, wound closure, and ENT products. Ethicon competes broadly in the surgical OR and is a relevant large-cap benchmark for Chitogel's commercial path, especially given CEO Edward Lamb's J&J heritage.
• Olympus Corporation: Global leader in endoscopic equipment with strong ENT/sinus surgery franchise. While Olympus focuses on endoscopes and instruments, it is a key channel partner and competitor in the FESS OR where Chitogel's hydrogel is deployed.

Direct peers

• Baxter International: Manufactures FloSeal Hemostatic Matrix, a leading hemostatic agent used in endoscopic sinus surgery. FloSeal is a direct competitor to Chitogel in controlling post-operative bleeding and is commonly used in FESS procedures as an alternative wound dressing/hemostatic.
• Hemostasis LLC: Developer of hemostatic agents (Surgiflo/Surgiflo Hemostatic Matrix) used in ENT and sinus surgery. Hemostasis LLC competes directly with Chitogel in the post-FESS bleeding control and wound healing category.
• Polyganics: Dutch medical device company that developed Nasopore, a biodegradable synthetic nasal packing widely used in FESS. Polyganics is a direct competitor to Chitogel in post-operative nasal dressing, with established surgeon adoption and distribution partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC8wuW_v9DhOd2WXavM9S3HQ
• LinkedInlinkedin.com/company/chitogel-limited

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chitogel